1.
Goldilocks Dosing of TKIs: A Dose that Is Just Right Leads to Optimal Outcomes
by Rini, Brian I
Clinical cancer research : an official journal of the American Association for Cancer Research, 01 July 2018, Vol.24(13), pp.2979-2980
2.
The context of blood vessels and response to VEGF-targeted therapy
by Rini, Brian I
Clinical cancer research : an official journal of the American Association for Cancer Research, 15 December 2013, Vol.19(24), pp.6647-9
3.
New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance.
by Rini, Brian I
Clinical cancer research : an official journal of the American Association for Cancer Research, March 1, 2010, Vol.16(5), pp.1348-1354
4.
Pharmacokinetically Guided Dosing of Oral Drugs: True Precision Oncology?
by Ornstein, Moshe C
Clinical cancer research : an official journal of the American Association for Cancer Research, December 1, 2016, Vol.22(23), pp.5626-5628
5.
The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
by Basappa, Naveen S
Cancer, March 15, 2011, Vol.117(6), pp.1183-1189
7.
Progression‐free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy
by Heng, Daniel Y. C.
Cancer, 15 June 2011, Vol.117(12), pp.2637-2642
8.
The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor‐targeted therapy
by Macfarlane, Robyn
Cancer, 15 January 2012, Vol.118(2), pp.365-370
9.
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib....
by Kim, Jenny J.
Cancer, April 1, 2012, Vol.118(7), p.1946(9)
10.
Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
by Rini, Brian I
Cancer, 15 February 2011, Vol.117(4), pp.758-67
11.
Phase I/II trial of subcutaneous interleukin‐2, granulocyte‐macrophage colony‐stimulating factor and interferon‐α in patients with metastatic renal cell carcinoma
by Garcia, Jorge A.
BJU International, January 2012, Vol.109(1), pp.63-69
12.
Progression‐free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?
by Halabi, Susan
Cancer, 01 June 2015, Vol.121(11), pp.1906-1906
13.
294 EFFECT OF PAZOPANIB ON MYELOID DERIVED SUPPRESSOR CELLS AND T CELL FUNCTION IN METASTATIC RENAL CELL CARCINOMA PATIENTS
by Khurana, Kiranpreet
The Journal of Urology, April 2013, Vol.189(4), pp.e119-e120
14.
Highlights in renal cell carcinoma from the 2012 American Society of Clinical Oncology Annual Meeting.
by Rini, Brian I
Clinical advances in hematology & oncology : H&O, September 2012, Vol.10(9 Suppl 15), pp.1-24
15.
Targeted therapy for patients with renal-cell carcinoma
by Rini, Brian I
Lancet Oncology, 2011, Vol.12(12), pp.1085-1087
16.
Toward individualized treatment in urologic oncology
by Rini, Brian I
Urologic Oncology: Seminars and Original Investigations, April 2015, Vol.33(4), pp.170-170
17.
Changing Landscape of Refractory Renal Cell Carcinoma.
by Rini, Brian I
Journal of oncology practice, May 2016, Vol.12(5), pp.422-423
18.
Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy.
by Rini, Brian I
Clinical advances in hematology & oncology : H&O, April 2011, Vol.9(4), pp.337-338
19.
Current and emerging first-line systemic therapies in clear cell renal cell carcinoma
by Rini, Brian I
Clinical advances in hematology & oncology : H&O, February 2018, Vol.16(2), pp.115-117
20.
Sorafenib in advanced renal cancer: a viewpoint by Brian I. Rini.(Guest Commentaries)
by Rini, Brian I.
Drugs, Feb 1, 2007, Vol.67(3), p.485(1)
